Havrix Junior (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix Junior is indicated for the prevention of hepatitis A infection in children according to approved immunization schedules.

• Primary prophylaxis for hepatitis A in children aged 12 months to 15 years.
• Use in outbreak settings to quickly confer immunity to susceptible pediatric populations.
• Administration as part of combination vaccination programs when recommended by health authorities.
• Boosting of immunity in previously vaccinated children who require a booster dose.
• Travel-related protection for children traveling to regions with high hepatitis A endemicity.

The safety profile of Havrix Junior reflects the typical reactions observed with inactivated viral vaccines. These reactions are generally self‑limiting and resolve without medical intervention.

Common

• Mild pain, redness, or swelling at the injection site.
• Low‑grade fever occurring within 24‑48 hours after vaccination.
• Transient fatigue or irritability in young children.
• Headache or mild muscle aches.
• Mild gastrointestinal upset such as nausea or loss of appetite.
• Temporary redness or warmth extending slightly beyond the injection site.

Serious

• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Neurological events including Guillain‑Barré syndrome, though rare.
• Severe local reaction with necrosis or abscess formation at the injection site (very rare).

Before administering Havrix Junior, healthcare providers should evaluate several precautionary factors to ensure safe use.

• Confirm that the child has no known severe allergy to any vaccine component, including algeldrate.
• Defer vaccination in individuals with acute moderate or severe illness until recovery.
• Assess for immunocompromised status; vaccine may be less effective but is not contraindicated.
• Review pregnancy status of the mother; safety data in pregnancy are limited.
• Avoid vaccination in children with a history of Guillain‑Barré syndrome following a previous hepatitis A vaccine.
• Observe the child for at least 15 minutes after injection for immediate hypersensitivity reactions.

Havrix Junior has a limited potential for drug interactions, but certain concomitant therapies warrant attention.

Avoid

• Concurrent administration with live viral vaccines (e.g., measles, mumps, rubella) in the same anatomical site; separate sites or intervals are recommended.

Use with caution

• Immunosuppressive agents (e.g., corticosteroids, chemotherapy) may reduce the antibody response to the vaccine.
• Antipyretics such as acetaminophen or ibuprofen can be used to manage post‑vaccination fever, but routine prophylactic use may blunt the immune response.
• Blood products or immunoglobulins given within 4 weeks before or after vaccination may interfere with seroconversion.
• Concurrent administration of other inactivated vaccines is generally acceptable, but monitoring for additive local reactions is advised.